Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

William Waling

Nurse Practitioner, Psychiatric/Mental Health Novi, MI Nurse Practitioner

NPI 1104587559 CMS profile 11385339

44725 Grand River Ave Ste 104, Novi, MI 48375

Open in the dashboard

General payments

$7,029

211 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Waling of Novi, MI is reported in the CMS Open Payments database as having received $7,029 across 211 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,271 68
2024 General $2,709 102
2023 General $1,208 25
2022 General $841 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Waling
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to William Waling were reported at $2,271. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year William Waling Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $841 $195 $66–$559 $149
2023 $1,208 $233 $82–$673 $160
2024 $2,709 $236 $84–$688 $164
2025 $2,271 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Otsuka America Pharmaceutical, Inc. $1,476 30 payments
  2. ITI, Inc. $1,177 35 payments
  3. Axsome Therapeutics, Inc. $660 10 payments
  4. AbbVie, Inc. $611 25 payments
  5. Neurocrine Biosciences, Inc. $539 21 payments
  6. Teva Pharmaceuticals USA, Inc. $508 14 payments
  7. Corium, Inc. $485 21 payments
  8. E.R. Squibb & Sons, L.L.C. $390 14 payments
  9. Lundbeck LLC $336 13 payments
  10. Alkermes, Inc. $269 5 payments
  11. Other $577 23 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,029 211 payments
Products named General payments · program years 2022–2025
  1. REXULTI Psychiatry $1,054 23 payments
  2. CAPLYTA $897 26 payments
  3. Auvelity $660 10 payments
  4. INGREZZA $539 21 payments
  5. Azstarys $485 21 payments
  6. ABILIFY MAINTENA $379 5 payments
  7. UZEDY $341 7 payments
  8. VRAYLAR Neuroscience $325 21 payments
  9. REXULTI Psychiatry $319 12 payments
  10. VRAYLAR Neuroscience $286 4 payments
  11. Other $2,823 80 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 25 drugs

Part D claims

590

Median for Nurse Practitioner: 389

Drug cost

$145,599

Median for Nurse Practitioner: $21,885

Branded share of claims

26.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 15 $119,354
Vraylar Cariprazine Hcl Brand 12 $16,748
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 71 $1,875
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 18 $896
Clomipramine Hcl Generic 11 $863
Hydroxyzine Hcl Generic 51 $705
Quetiapine Fumarate Er Quetiapine Fumarate Brand 11 $631
Gabapentin Generic 41 $542
Aripiprazole Generic 20 $496
Bupropion Xl Bupropion Hcl Brand 20 $491

The 10 drugs with the highest cost, of 25 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$9,283

Medicare's payments for the services billed

Medicare patients

26

Average age 59

Services billed

122

14 women, 12 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 69%
High blood pressure 65%
Arthritis 46%
Atrial fibrillation 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Otsuka America Pharmaceutical, Inc. $352
  • Lundbeck LLC $91
$442 — —
CAPLYTA
  • ITI, Inc. $314
$314 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $303
$303 — —
Auvelity
  • Axsome Therapeutics, Inc. $288
$288 — —
Azstarys
  • Corium, Inc. $233
$233 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

211 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record